Ongoing OS follow-up continues to indicate a positive trend favoring the combination therapy (hazard ratio, 0.827; 95% CI, 0.636–1.074).
← all excerpts
Transforming Breast Cancer Care: Cutting-Edge Insights and Future Directions.
1
—
—
Ongoing OS follow-up continues to indicate a positive trend favoring the combination therapy (hazard ratio, 0.827; 95% CI, 0.636–1.074).